|2. Switch to a TNFi biologic over switching to an IL-17i biologic (PICO 46)|Very low|
|Conditional recommendation based on very-low-quality evidence; may consider switching to an IL-17i biologic if the patient has contraindications to TNFi biologics, congestive heart failure, previous serious infections, recurrent infections, or demyelinating disease, or if the patient has severe psoriasis.ยง| |
|3. Switch to a TNFi biologic over switching to an IL-12/23i biologic (PICO 45)|Very low|
|Conditional recommendation based on very-low-quality evidence; switching to an IL-12/23i biologic is not considered since recent trials in axial SpA were stopped.| |
|4. Switch to an IL-17i biologic over switching to an IL-12/23i (PICO 47)|Very low|
|Conditional recommendation based on very-low-quality evidence; switching to an IL-12/23i biologic is not considered since recent trials in axial SpA were stopped.| |